tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Marsella R et al. | Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. | 2004 | Vet. Dermatol. | pmid:15500481 |
| Marsella R and Nicklin CF | Investigation on the use of 0.3% tacrolimus lotion for canine atopic dermatitis: a pilot study. | 2002 | Vet. Dermatol. | pmid:12174182 |
| Banovic F et al. | Therapeutic effectiveness of calcineurin inhibitors in canine vesicular cutaneous lupus erythematosus. | 2017 | Vet. Dermatol. | pmid:28439997 |
| Olivry T et al. | Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. | 2010 | Vet. Dermatol. | pmid:20456716 |
| Scholz FM et al. | Focal metatarsal fistulae syndrome affecting a greyhound dog successfully treated with topical 0.1% tacrolimus ointment. | 2015 | Vet. Dermatol. | pmid:26216245 |
| Nell B et al. | The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study. | 2005 Jan-Feb | Vet Ophthalmol | pmid:15644099 |
| Berdoulay A et al. | Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca. | 2005 Jul-Aug | Vet Ophthalmol | pmid:16008701 |
| Hafizi S et al. | Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. | 2004 May-Jun | Vascul. Pharmacol. | pmid:15607500 |
| Dissemond J et al. | Successful treatment of stasis dermatitis with topical tacrolimus. | 2004 | VASA | pmid:15623206 |
| Woodward RS et al. | The long-term outcomes and costs of diabetes mellitus among renal transplant recipients: tacrolimus versus cyclosporine. | 2011 | Value Health | pmid:21315636 |
| Christ B et al. | Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. | 2001 | Urology | pmid:11597545 |
| Harmon JD et al. | Stuttering priapism in a liver transplant patient with toxic levels of fk506. | 1999 | Urology | pmid:10754131 |
| Chkhotua AB et al. | Kidney transplantation from living-unrelated donors: comparison of outcome with living-related and cadaveric transplants under current immunosuppressive protocols. | 2003 | Urology | pmid:14665344 |
| Ebert AK et al. | [Topical therapy of balanitis xerotica obliterans in childhood. Long-term clinical results and an overview]. | 2007 | Urologe A | pmid:17994212 |
| [Tacrolimus--a new perspective in kidney transplantation]. | 1996 | Urologe A | pmid:9022401 | |
| Nomura T et al. | Enhancement by cyclosporin A of taxol-induced apoptosis of human urinary bladder cancer cells. | 2002 | Urol. Res. | pmid:12086014 |
| Hwang MT and Goldfarb DS | Uric acid stones following hepatic transplantation. | 2004 | Urol. Res. | pmid:15565437 |
| Veroux P et al. | Severe neurotoxicity in tacrolimus-treated living kidney transplantation in two cases. | 2003 | Urol. Int. | pmid:14646448 |
| Pichler R et al. | De novo renal cell carcinoma in a kidney allograft with focus on contrast-enhanced ultrasound. | 2014 | Urol. Int. | pmid:25115614 |
| Naderi GH et al. | Tacrolimus rescue therapy for corticosteroid-resistant and polyclonal antibody-resistant kidney allograft rejections. | 2009 | Urol J | pmid:19241339 |